The VBC Economics of GLP-1s: Why Selection Beats Volume

Why This Landed on My Radar

Here’s a claim you’ll hear at every conference this year: “Metabolic disease costs the system a fortune, so treating it with GLP-1s saves money.” It’s intuitive, it’s well-intentioned, and as a blanket statement it’s not what the evidence shows. The truth is more useful - and it points to a real strategy for any practice in a value-based contract. Let’s do the math honestly.

The Trap: Burden Is Not the Same as Offset

Metabolic disease is one of the largest cost drivers in American healthcare. That part is true. But the total burden of a disease and the avoidable, near-term slice of it are very different numbers - and GLP-1s are expensive enough that the gap matters.

The cleanest evidence is the Congressional Budget Office’s analysis of covering anti-obesity medications in Medicare. Per patient, the drug runs roughly $5,600 a year, declining toward $4,300 by 2034. The offsetting health savings? About $50 per patient in the first year, reaching only ~$650 by 2034. The avoided hospitalizations and ER visits are real - they’re just an order of magnitude smaller than the drug cost in the near term. Net, the CBO projected covering these drugs would increase federal spending by about $35 billion from 2026 to 2034.

So the broad, short-term version of “it pays for itself” doesn’t hold. That’s the part worth saying out loud before a practice bets its shared-savings number on it.

The Reframe That Actually Matters: Cost-Effective ≠ Cost-Saving

Here’s where it turns constructive. In late 2025, the Institute for Clinical and Economic Review (ICER) - the independent value watchdog, not a manufacturer - found that semaglutide and tirzepatide for obesity are cost-effective: roughly $53,000-$61,000 per quality-adjusted life year, comfortably below their value benchmark. Translation: these drugs are worth what they cost in health terms. They deliver real value per dollar.

They just don’t deliver it as a smaller bill - at least not soon. That’s the distinction that gets lost: a therapy can be excellent value and still not save money. ICER made the point bluntly - even at cost-effective prices, fewer than 1% of eligible patients could be treated before blowing through a payer’s annual budget-impact threshold. Cost-effective, unaffordable at scale, not cost-saving. All three at once.

For a VBC practice, internalizing that single sentence changes how you deploy these drugs.

Where the Offset Is Real: Target the High-Risk Subgroups

The cost-offset doesn’t disappear - it concentrates. And it concentrates exactly where your sickest, most expensive patients are:

• Type 2 diabetes + chronic kidney disease. Avoiding dialysis is one of the largest cost events in any panel. Modeling based on the FLOW trial found semaglutide can be cost-saving in this group - the drug cost fully offset by avoided kidney failure. (Caveat: lifetime horizon, manufacturer-funded, non-US pricing - directionally important, not a blank check.)
• Established cardiovascular disease. Semaglutide’s CV-event reduction makes it cost-effective for secondary prevention - but the analyses show this is price-sensitive: it pencils out at the lower cash price, not always at the net price. As prices fall, this group moves firmly into the black.
• HFpEF and MASH are the next frontiers, with the outcomes data still maturing.

The pattern is unmistakable: the math works where the avoided events are large and relatively near-term. It struggles where you’re treating lower-risk patients for weight alone and hoping for downstream savings that arrive slowly, if at all.

The Two Multipliers: Adherence and Time Horizon

Two realities decide whether even a well-selected patient pays off:

1. Adherence. Roughly 40% of patients discontinue within a year, even in the most recent and best-performing cohorts. Every drop-out is drug cost spent without the durable risk reduction that justified it. Adherence support isn’t a nicety - it’s the difference between an investment and a write-off.
2. The horizon mismatch. The clinical benefit accrues over 5-20 years; most VBC contracts settle annually with patients who change payers. The savings can be completely real at the system-and-lifetime level and still land in someone else’s ledger by the time they arrive. Capturing the value you create requires contract structures - longer attribution, condition-specific arrangements - that match the clinical time horizon. That’s a payer-negotiation problem as much as a clinical one.

What This Means for Your Practice

The strategy that falls out of the evidence isn’t “prescribe more.” It’s prescribe smarter:

1. Select for the offset. Prioritize the high-risk cardiometabolic and renal patients where the math works near-term - not just the highest BMI.
2. Protect adherence. A patient who stops at month four cost you the drug and bought you nothing.
3. Mind the contract. Know your attribution window and push for terms that let you capture long-horizon value.
4. Measure what the contract pays for. Track the avoided events, not just pounds lost.

This is the difference between GLP-1s as a cost center and GLP-1s as a value-based-care advantage - and it’s entirely a function of which patients, kept on therapy, under what contract. That’s not a prescribing question. It’s a panel-intelligence question.

This is the capstone of Peptides in Primary Care, bridging to our value-based-care series. PayerVantage helps independent practices identify exactly which patients drive cost and opportunity under their specific contracts - turning “GLP-1s are good for value-based care” from a slogan into a patient-by-patient strategy. [See how →]

Educational content for clinicians; not medical or financial advice. Economic figures per CBO (2024), ICER (2025), and peer-reviewed cost-effectiveness analyses; current as of June 2026.